Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | KEYNOTE-204 in R/R classical Hodgkin lymphoma

John Kuruvilla • 26 May 2020
ASCO 2020
Hodgkin Lymphoma Pembrolizumab
KEYNOTE-204

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, details the results of the KEYNOTE-204 study (NCT02684292) which aimed to determine the benefit of pembrolizumab against brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from John Kuruvilla

Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
1:06
Updates on the Phase Ib KEYNOTE-013 trial: pembrolizumab in NHL
John Kuruvilla • 12 Dec 2022
1:18
Hodgkin lymphoma highlights at ASH 2022 and future outlooks
John Kuruvilla • 12 Dec 2022
0:49
Abbv-319: a novel, CD19-GRM antibody-drug conjugate being explored for R/R B-cell malignancies
John Kuruvilla • 12 Dec 2022

Related Videos

2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:50
Results of the EuroNet-PHL-C1 trial: omission of radiotherapy in children and adolescents with cHL
Christine Mauz-Körholz • 8 Dec 2023
1:17
KEYNOTE-667: pembrolizumab plus COPDAC-28 for high-risk cHL with slow early response to OEPA
Christine Mauz-Körholz • 8 Dec 2023
0:52
Managing late effects of treatment in pediatric patients with Hodgkin lymphoma
Christine Mauz-Körholz • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals